Antidiabetic Investigations of Aqueous and Ethanol Extracts of Terminalia macroptera (Guill. & Perr.) Stem Bark in Streptozotocin-Induced Diabetic Wistar Rats doi.org/10.26538/tjnpr/v5i6.25
Main Article Content
Abstract
Diabetes mellitus always-increasing prevalence has prompted investigations into plants traditionally extolled for antidiabetic properties. One of such is Terminalia macroptera, a member of the Combretaceae family that grows in the Savannah. Consequently, this study evaluated the antidiabetic potentials of the stem bark aqueous (AE) and ethanol extracts (EE). Wistar rats were allotted into 2 controls (nondiabetic and diabetic) and 2 treatment (diabetic) groups (n = 5). All diabetic groups were induced intraperitoneally with streptozotocin (55 mg/kg body weight) from which respective treatment groups were orally administered AE and EE (200 mg/kg/day), while controls received water for 70 days. Thereafter, the concentrations of glucose, lipids, insulin, C-peptide, testosterone, and α-amylase activities were measured in serum. Liver homogenates were evaluated for glycogen and antioxidant status, while mRNA expressions of PDX-1, insulin-1, TNF-α, and Il-1 β were examined in β-cell. AE and EE, respectively, caused 55.66% and 78.95% reductions in elevated glucose when compared to control. However, only EE-treated rats had glucose and glycogen levels normalized besides increased insulin concentration (P < 0.05 vs diabetic control, DC). Both extracts significantly decreased lipid profiles but caused increase in antioxidant levels (P < 0.05 vs DC). In contrast to AE, EE slightly increased C-peptide and testosterone concentrations but significantly enhanced α-amylase activity. Up-regulated insulin gene expressions remained unabated, but those of PDX-1 and inflammatory factors were downregulated by both extracts (P < 0.05 vs DC). Terminalia macroptera stem bark was revealed to possess antidiabetic properties that were better expressed by EE through insulin stimulation.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Sanhueza L, Durruty P, Vargas C, Vignolo P, Elgueta K. Diabetes Mellitus: A Group of Genetic-Based Metabolic Diseases. In: Khan J, Hsieh P-S. (eds.). An Understanding to Anthropoid Autosomal Diseases. London: IntechOpen, 2019. 20 p.
Ormazabal V, Nair S, Elfeky O, Aguayo C, SalomonC, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018; 17:122.
Chillarón JJ, Le-Roux, JAF, Benaiges D, Pedro-Botet J. Type 1 diabetes, metabolic syndrome and cardiovascular risk. Metabol. 2014; 63(2):181-187.
Gaikwad SB, Mohan GK, Rani MS. Phytochemicals for Diabetes Management. Pharm Crop. 2014; 5(1):11-28.
Zhang XR, Joseph Kaunda JS, Zhu HT, Wang D, Yang CR, Zhang YJ. The Genus Terminalia (Combretaceae): an ethnopharmacological, phytochemical and pharmacological review. Nat Prod Bioprospect. 2019; 9(6):357-392.
Ibrahim H. Pharmacognostic Studies of the leaves of Terminalia macroptera. Nig J Nat Prod Med. 2005; 9:14-18.
Conrad J, Vogler B, Reeb S, Klaiber I, Papajewski S, Roos G, Vasquez E, Setzer MC, Kraus W. Isoterchebulin and 4, 6- O-terchebuloyl-D-glucose, novel hydrolysable tannins from Terminalia macroptera. J Nat Prod. 2001; 64:294-299.
Haidara M, Haddad M, Denou A, Marti G, BourgeadeDelmas S, Sanogo R. In vivo validation of anti-malarial activity of crude extracts of Terminalia macroptera, a Malian medicinal plant. Malar J. 2018; 17:68.
Silva O, Ferreira E, Pato MV, Canica M, Gomes ET. In vitroanti-Neisseria gonorrhoeae activity of Terminalia macroptera leaves. FEMS Microbiol Lett. 2002; 211:203-206.
Silva O, Viegas S, de Mello-Sampayo C, Costa MJ, Serrano R, Cabrita J, Gomes ET. Anti-Helicobacter pylori activity of Terminalia macroptera root. Fitoter. 2012; 83:872-876.
Sanogo R. Terminalia macroptera Guill. & Perr. In: Schmelzer, G.H. & Gurib-Fakim, A. (Editors). Medicinal Plants/Plantes Médicinales 2. PROTA, Wageningen, Netherlands: PROTA. 2013; 11(2): 417.
Akpovona AE, Onoagbe IO, Prohp TP. Proximate and phytochemical analyses of mature stem bark of Terminalia macroptera Guill. & Perr. J Chem Soc Nig. 2016a; 4(1):111-116.
Akpovona AE and Onoagbe IO. Investigation of haematological effects of Terminalia macroptera stem bark via platelet-to-lymphocyte ratio among other blood parameters in Wistar rats. Biokemistri. 2018; 30(1):32-41.
Zou YF, Ho GTT, Malterud KE, Le NHT, Inngjerdingen KT, Barsett H, Diallo D, Michaelsen TE, Paulsen BS. Enzyme inhibition, antioxidant and immunomodulatory activities, and brine shrimp toxicity of extracts from the root bark, stem bark and leaves of Terminalia macroptera. J Ethnopharmacol. 2014b; 155(2):1219-1226.
Akpovona AE, Onoagbe IO, Eze GI, Omonkhua AA. Acute and subchronic toxicity studies of ethanol extract of Terminalia macroptera stem bark in Wistar albino rats. J Med Biomed Res. 2016b; 15(1):62-73.
Roehrig KL and Allred JB. Direct enzymatic procedure for the determination of liver glycogen. Anal Biochem. 1974; 58(2):414-421.
Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem. 1966; 6:24.
Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974; 20:470-475.
Chen Y, Zhang X, Pan B, Jin X, Yao H, Chen B, Zou Y, Ge J, Chen H. A modified formula for calculating low-density lipoprotein cholesterol values. Lipids Health Dis. 2010; 9:52.
Marklund S and Marklund G. Involvement of the superoxide anion radical in the autooxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem.1974; 47:469-474.
Slaughter MR and O’brien PJ. Determination of catalase activity. Clin Biochem. 2001; 33:525. Patent: WO2001034831A2; WO 2001034831A3.
Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959; 82:70-77.
Tietz NW. Clinical Guide to Laboratory Tests. (3rd ed). W. B. Saunders. Philadelphia: USA. 1995. 268-273 p.
Rines AK, Sharabi K, Tavares CDJ, Puigserver P. Targeting hepatic glucose output in the treatment of type 2 diabetes. Nat Rev Drug Discov. 2016; 15(11):786-804.
Mithieux G, Rajas F, Gautier-Stein A, Soty M. Adaptation of Hepatic, Renal, and Intestinal Gluconeogenesis During Food Deprivation. In: Preedy V., Patel V. (eds) Handbook of Famine, Starvation, and Nutrient Deprivation. Springer International Publishing, Cham. 2017; pp 1-15.
Zhang Z, Liew CW, Handy DE, Zhang Y, Leopold JA, Hu J, Guo L, Kulkarni RN, Loscalzo J, Stanton RC. High glucose inhibits glucose-6-phosphate dehydrogenase, leading to increased oxidative stress and β-cell apoptosis. FASEB J. 2010; 24 (5):1497-1505.
Zhang X, Yang S, Chen J, Su Z. Unraveling the regulation of hepatic gluconeogenesis. Front. Endocrinol. 2019; 9:802.
Bhowmik B, Siddiquee T, Mujumder A, Afsana F, Ahmed T, Mdala IA, do V Moreira NC, Khan AKA, Hussain A, Holmboe-Ottesen G, Omsland TK. Serum lipid profile and its association with diabetes and prediabetes in a rural bangladeshi population. Int J Environ Res Pub Health. 2018; 6; 15(9):1944.
Hurtado-Roca Y, Bueno H, Fernandez-Ortiz A, Ordovas JM, Ibañez B, Fuster V, Rodriguez Artalejo F, Laclaustra M. Oxidized LDL is associated with metabolic syndrome traits independently of central obesity and insulin resistance. Diabetes. 2017; 6:474-482.
Moukette BM, Pieme CA, Biapa PCN, Moor VJA, Berinyuy E, Ngogang JY. Afrostyrax lepidophyllus extracts exhibit in vitro free radical scavenging, antioxidant potential and protective properties against liver enzymes ion mediated oxidative damage. BMC Res Notes 2015; 8:344.
Nurdiana S, Goh YM, Ahmad H, Dom S, Azmi NS, Zin NSNM, Ebrahimi M. Changes in pancreatic histology, insulin secretion and oxidative status in diabetic rats following treatment with Ficus deltoidea and vitexin. BMC Compl Altern Med. 2017; 17:290.
Cheng Y, Kang H, Shen J, Hao H, Liu J, Guo Y, Mu Y, Han W. Beta-cell regeneration from vimentin+ /MafB+cells after
STZ-induced extreme beta-cell ablation. Sci Rep. 2015; 5:11703.
Wahren J. C-peptide and the pathophysiology ofmicrovascular complications of diabetes. J Intern Med. 2017; 281(1):3-6.
Dimakopoulou A, Jayasena CN, Radia UK, Algefari M, Minhas S, Oliver N, Dhillo WS. Animal models of diabetesrelated male hypogonadism. Front Endocrinol (Lausanne). 2019; 10:628.
Chung TH, Kwon YJ, Lee YJ. High triglyceride to HDL cholesterol ratio is associated with low testosterone and sex hormone-binding globulin levels in middle-aged and elderly men, The Aging Male, 2020; 23(2):93-97.
Zhuang L, Su J, Zhang X, Huang H, Zhao L, Xu F, Chen T, Wang XQ, Wu G, Wang XH. Serum amylase levels in relation to islet β cell function in patients with early type 2 diabetes. PLoS ONE. 2016; 11(9):e0162204.
Liu H, Yang J, Li L, Shi W, Yuan X, Wu L. The natural occurring compounds targeting endoplasmic reticulum stress. Evid-Based Compl Altern Med. 2016; 2016:13.
Lipson KL, Ghosh R, Urano F. The role of IRE1α in the degradation of insulin mRNA in pancreatic β-cells. PLoSONE. 2008; 3(2):e1648.
Riaz TA, Junjappa RP, Handigund M, Ferdous J, Kim HR, Chae HJ. Role of endoplasmic reticulum stress sensor IRE1α in cellular physiology, calcium, ROS signaling, and metaflammation. Cells 2020; 9(5):1160.
Welsh M, Nielsen DA, MacKrell AJ, Steiner DF. Control of insulin gene expression in pancreatic beta-cells and in an insulin-producing cell line, RIN-5F cells. II. Regulation of insulin mRNA stability. J Biol Chem. 1985; 260(25):13590-13594.
Boland BB, Rhodes CJ, Grimsby JS. The dynamic plasticity of insulin production in β-cells. Mol Metab. 2017; 6(9):958-973.
Gothai S, Ganesan P, Park SY, Fakurazi S, Choi DK, Arulselvan P. Natural phyto-bioactive compounds for the treatment of type 2 diabetes: Inflammation as a Target, Nutrients. 2016; 8(8):461.
Rhee M, Lee SH, Kim JW, Ham DS, Park HS, Yang HK, Shin JY, Cho JH, Kim YB, Youn BS, Sul HS, Yoon KH. Preadipocyte factor 1 induces pancreatic ductal cell differentiation into insulin-producing cells. Sci Rep. 2016; 6:23960.